Showing results (21-30 of 80) with videos related to

Sort By:
Pageof 8
Blood|September 7, 2014
JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosisXiaoli Wang, Fei Ye, Joseph Tripodi, et al.
Leukemia & Lymphoma|November 30, 2013
Acute myeloid leukemia presenting with panhypopituitarism or diabetes insipidus: a case series with molecular genetic analysis and review of the literatureElizabeth H Cull, Justin M Watts, Martin S Tallman, et al.
Mediterranean Journal of Hematology and Infectious Diseases|July 15, 2016
Bisphosphonates in Langerhans Cell Histiocytosis: An International Retrospective Case SeriesDeepak Chellapandian, Polyzois Makras, Gregory Kaltsas, et al.
Leukemia & Lymphoma|June 1, 2016
Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasmsTariq I Mughal, Omar Abdel-Wahab, Raajit Rampal, et al.
Acta Haematologica|November 14, 2012
Translocation t(11;17) in de novo myelodysplastic syndrome not associated with acute myeloid or acute promyelocytic leukemiaMuhamed Baljevic, Omar Abdel-Wahab, Raajit Rampal, et al.
Blood|June 7, 2019
Oral idasanutlin in patients with polycythemia veraJohn Mascarenhas, Min Lu, Heidi Kosiorek, et al.
Haematologica|November 20, 2025
JAK inhibitor selection in challenging scenarios of myelofibrosis: a reviewPankit Vachhani, Ruben Mesa, John Mascarenhas, et al.
Future Oncology (London, England)|March 7, 2026
POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinibPankit Vachhani, Abdulraheem Yacoub, Raajit Rampal, et al.
Blood|March 21, 2012
Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcomeSu-Jiang Zhang, Raajit Rampal, Taghi Manshouri, et al.
Leukemia Research|August 30, 2016
Telomere length and associations with somatic mutations and clinical outcomes in acute myeloid leukemiaJustin M Watts, Bogdan Dumitriu, Patrick Hilden, et al.
Pageof 8